Médicament 📍 BR

DAPAGLIFLOZINA PROPANODIOL

90,90 R$

Prix max. consommateur (CMED)

Analogs of DAPAGLIFLOZINA PROPANODIOL

Find cheaper analogs and generic equivalents for DAPAGLIFLOZINA PROPANODIOL.

Buy now on Amazon Search results on Amazon.ca — as an Amazon Associate we earn from qualifying purchases.

Ingredients

Principe actif : dapagliflozine propanodiol

Aperçu du produit

About DAPAGLIFLOZINA PROPANODIOL

DAPAGLIFLOZINA PROPANODIOL is a prescription medication used to manage blood glucose levels in adults with type 2 diabetes mellitus. It belongs to the class of sodium-glucose co‑transporter 2 (SGLT2) inhibitors, which work by reducing glucose reabsorption in the kidneys, thereby increasing urinary glucose excretion. The formulation contains the active ingredient dapagliflozine propanodiol, delivered in a stable, water‑soluble form that facilitates absorption and bioavailability. The drug is intended for use under the supervision of a qualified healthcare professional and should be taken as directed in the prescribing information. Patients should be monitored for renal function and hydration status during therapy. DAPAGLIFLOZINA PROPANODIOL is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis.

Key Benefits & Uses

Improves glycemic control by lowering fasting and post‑prandial blood glucose levels.
Helps reduce the need for additional antidiabetic medications in many patients.
May contribute to modest weight loss and blood pressure reduction as part of comprehensive diabetes management.

Active Ingredient & Action

The active component, dapagliflozine propanodiol, selectively inhibits SGLT2 transporters in the proximal renal tubules. This inhibition decreases glucose reabsorption, leading to increased glucose excretion in the urine. The mechanism is independent of insulin secretion, making it a valuable option for patients with insulin resistance or impaired insulin secretion.

Important Notes

Patients should be advised to maintain adequate fluid intake to mitigate the risk of dehydration. Regular monitoring of kidney function is essential, as the drug’s efficacy and safety depend on renal performance. DAPAGLIFLOZINA PROPANODIOL should not be used in patients with severe renal impairment or end‑stage renal disease. It is also contraindicated in individuals with a history of hypersensitivity to dapagliflozine or any component of the formulation. Always consult a healthcare provider before initiating or discontinuing therapy.